Cargando…
Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST). Durable discontinuation of ST reflects the resolution of active chronic GvHD. We evaluated the factors associated with durable ST discontinuation, defined as cessation of all ST for ≥12 m...
Autores principales: | Chen, George L., Onstad, Lynn, Martin, Paul J., Carpenter, Paul, Pidala, Joseph, Arai, Sally, Cutler, Corey, Hamilton, Betty K., Lee, Stephanie J., Arora, Mukta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890023/ https://www.ncbi.nlm.nih.gov/pubmed/35615925 http://dx.doi.org/10.3324/haematol.2021.279814 |
Ejemplares similares
-
Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival
por: Pidala, Joseph, et al.
Publicado: (2021) -
The development of graft-versus-host disease prophylaxis
por: Cutler, Corey
Publicado: (2023) -
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021) -
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021) -
Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)